Literature DB >> 32402168

Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer.

Robin K Kelley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32402168     DOI： 10.1056/NEJMe2004851

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

Review 1.  Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention.

Authors:  Joseph H Yacoub; David Mauro; Andrew Moon; Aiwu R He; Mustafa R Bashir; Christine C Hsu; Thomas M Fishbein; Lauren M B Burke
Journal:  Abdom Radiol (NY)       Date:  2021-04-16

Review 2.  Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.

Authors:  Layana Biglow; Sara Ashraf; Mohamed Alsharedi
Journal:  Stem Cell Investig       Date:  2021-11-10

Review 3.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 4.  Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.

Authors:  Stephen P Hack; Andrew X Zhu; Yulei Wang
Journal:  Front Immunol       Date:  2020-11-05       Impact factor: 7.561

Review 5.  Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma.

Authors:  Gabriella Aitcheson; Anjana Pillai; Bassam Dahman; Binu V John
Journal:  Curr Hepatol Rep       Date:  2021-02-01

Review 6.  Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.

Authors:  Jingyi Zhou; Weiyu Wang; Qi Li
Journal:  J Exp Clin Cancer Res       Date:  2021-02-17

7.  Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma.

Authors:  Kevin P Labadie; Andrew D Ludwig; Adrienne L Lehnert; Donald K Hamlin; Aimee L Kenoyer; Kevin M Sullivan; Sara K Daniel; Tara N Mihailovic; Jonathan G Sham; Johnnie J Orozco; Raymond S Yeung; Delphine L Chen; D Scott Wilbur; Robert S Miyaoka; James O Park
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

8.  Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.

Authors:  Guosheng Yuan; Yangda Song; Qi Li; Xiaoyun Hu; Mengya Zang; Wencong Dai; Xiao Cheng; Wei Huang; Wenxuan Yu; Mian Chen; Yabing Guo; Qifan Zhang; Jinzhang Chen
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

9.  Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.

Authors:  Guosheng Yuan; Xiao Cheng; Qi Li; Mengya Zang; Wei Huang; Wenzhe Fan; Tao Wu; Jian Ruan; Wencong Dai; Wenxuan Yu; Mian Chen; Yabing Guo; Xiaoyun Hu; Jinzhang Chen
Journal:  Onco Targets Ther       Date:  2020-12-09       Impact factor: 4.147

Review 10.  Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Alessandro Di Federico; Giorgio Frega; Andrea Palloni; Simona Tavolari; Giovanni Brandi
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.